Insurance Appeals for Duchenne Families

Insurance appeals for Duchenne muscular dystrophy families are the formal process of contesting a payer’s refusal to cover a treatment, equipment, therapy, or service that the medical team considers necessary. For approved DMD therapies in particular, denials and prior-authorisation disputes have become a routine part of the access experience. Most denials can be reversed when families and clinicians put together a complete, well-documented appeal. The work is unglamorous and the timelines are slow, but the success rate, with persistence, is high.

This post is a practical guide. The specifics depend on country, payer, and policy, and individual cases should involve the care team, a social worker, and, where helpful, a patient organisation.

Why appeals matter so much in DMD

Two structural facts make appeals central to DMD access. First, DMD treatment is expensive: gene therapies, exon-skipping infusions, vamorolone, givinostat, and equipment costs all sit in the specialty range. Second, payer policies often lag behind regulatory approvals and clinical guidelines, leaving families to push policies forward case by case.

A coalition of certified Duchenne care centre directors has documented broad concern about payer variability and high denial rates even after initial approvals. (Collective Statement on Patient Access to Approved Therapies, PPMD Certified Duchenne Care Center Directors, PMC)

For background on what feeds these decisions, see the reported piece on drug approval and public policy and the comparative perspective on access.

Anatomy of a denial

A typical insurance denial letter has several elements families can use:

• The specific reason cited (medical necessity, not covered by policy, experimental, off-label, prior-authorisation incomplete, or other).
• A reference to the policy or clinical criteria the decision was based on.
• An appeal deadline and instructions for how to file.
• Sometimes, the name and credentials of the medical reviewer.

Read the letter carefully. Often the reason is narrower than “not covered” — it may be missing documentation, a coding issue, or a policy that has been updated and not yet reflected in the local decision system. Knowing the specific reason determines the type of appeal.

The first-level appeal

The first appeal goes back to the same payer for reconsideration. Standard elements include:

• A formal cover letter from the family, requesting reconsideration.
• A letter of medical necessity from the prescribing clinician, restating the diagnosis, the rationale for the requested treatment, and the expected outcome.
• Supporting documentation: relevant clinical records, prior assessment results, and references to clinical practice guidelines.
• For specialty therapies, supporting statements from neuromuscular specialists or certified Duchenne care centre directors.
• A clear ask: approve the requested treatment for the requested duration, citing the policy or clinical criteria that supports approval.

Parent Project Muscular Dystrophy maintains an Insurance Access and Coverage Center with sample letters for families, physical therapists, and medical providers. (PPMD, Access and Coverage Resources for New Therapies)

For background on broader financial navigation, see financial planning and insurance for Duchenne families.

The second-level and external appeals

When a first-level appeal is denied, most systems allow:

• A second-level internal appeal, often with a different reviewer at the payer.
• An external review by an independent organisation, sometimes mandated by national or state regulation.
• In some countries, a regulatory complaint or ombudsman process.
• Litigation, as a last resort, often with the support of advocacy organisations.

External reviews have a meaningfully higher success rate for many DMD families than internal appeals alone, particularly for specialty therapies where the payer’s internal logic has not caught up with regulatory or clinical reality.

What strengthens an appeal

A few patterns consistently improve appeal outcomes:

• A specific, citable letter of medical necessity rather than a generic statement.
• References to current FDA, EMA, or local regulatory approvals and the relevant labels.
• Clinical practice guidelines such as the 2018 international DMD care considerations.
• Outcome data showing why this patient meets the criteria the payer cites.
• A clear chronology that anticipates the payer’s likely counter-arguments.
• Where applicable, statements from a certified Duchenne care centre or other recognised neuromuscular specialist.
• For specialty drug appeals, evidence of prior-authorisation compliance and any conditions the prior approval imposed.

Manufacturer copay programs and patient assistance

While the appeal is in progress, several mechanisms can bridge the gap:

• Manufacturer copay support programs for many DMD specialty therapies.
• Patient assistance programs for low-income patients and the uninsured.
• Independent disease-specific copay foundations such as The Assistance Fund and Patient Advocate Foundation.
• Patient organisation emergency grants for equipment and modifications not covered by insurance.

Importantly, manufacturer copay programs do not apply to government-insured patients in the United States. For that population, the disease-specific copay foundations and patient organisations carry more weight.

For background, see financial planning and insurance for Duchenne families.

Working with the right professionals

A practical team for an appeal often includes:

• The treating neuromuscular clinician who writes the letter of medical necessity.
• A clinic-based or hospital-based social worker familiar with appeals.
• A patient organisation case worker, when available, who knows the local payer landscape.
• A specialty-pharmacy case manager, for specialty drug appeals.
• A patient advocacy attorney, for cases that escalate beyond external review.

A single point of contact within the family who keeps the chronology in writing makes everything else easier.

For background, see the DMD care team explained and working with DMD patient organizations.

What to do while waiting

Appeals take time. Practical steps that protect the patient during the process:

• Continue treatment when clinically appropriate and when bridge funding is available.
• Document any deterioration, missed doses, or delayed care during the appeal period.
• Keep a written log of all calls, letters, and submissions, with dates and reference numbers.
• Loop the care team into the timeline; they sometimes need to escalate on the clinical side.
• Loop the patient organisation in; they may have leverage with specific payers that families do not.

What families can ask the payer directly

A short list of useful questions for the appeal phone calls:

• What is the specific clinical criterion the denial is based on, and where is it published?
• Who is the medical reviewer for this case, and what are their credentials?
• What additional documentation would lead to approval at this stage?
• What is the deadline for the next level of appeal?
• Is there an expedited appeal process for time-sensitive cases?

Documentation of the answers becomes part of the appeal record.

What is still uncertain

Insurance policy and payer behaviour evolve quickly. The landscape in 2026 is not the landscape in 2030. Patient organisations update their guidance regularly, and the right strategy for a specific case in a specific year may differ from what worked previously.

The reasonable framing is that insurance appeals in DMD are a structured, persistent process, not a one-letter event. Most denials can be reversed when the case is documented thoroughly and the right teams are involved. The decisions belong to the family in coordination with the clinical and advocacy teams.

For related reading, see financial planning and insurance for Duchenne families, DMD treatment cost, DMD treatment access by country, working with DMD patient organizations, and the reported pieces Duchenne, drug approval, and public policy and The Same Disease, Different Countries.

Disclaimer: This post is informational and does not constitute medical or legal advice. Decisions should be made with the care team, social workers, and qualified professionals.